2020.5 NDA/BLA Inspection Schedule by CFDI for NMPA

May 2020 NDA/BLA Inspection Schedule by CFDI for NMPA:

No.
Acceptance number
Company
Products
1
CXHS1800031
Simcere
d-borneol
1
CYHS1800020
Ascletis
Ravidasvir hydrochloride tablet
1
CYHS1800032
Simcere
d-borneol and edaravone Injection

Popular posts from this blog

Shanghai Xunhe Pharma’s CDK4/6 Inhibitor XH-30002 IND Accepted by Chinese NMPA

Guideline on the Submission of Clinical Trial Data in China (2020.5 Draft for Public Review)

Drug Review Package of Chinese New Chemical or Biologic Drug